

**Prof. Christoph Huber, M.D., Dr. h. c.
Member of the Supervisory Board**

Year of birth	1944
Nationality	Austrian
Place of residence	Innsbruck and Vienna, Austria
Main occupation	Professor Emeritus of Johannes Gutenberg University Mainz
Initial appointment	2008
End of current appointment	2023
Memberships in statutory Supervisory Boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises	
Association for Cancer Immunotherapy CIMT e.V., Mainz, Germany (non-listed company)	Executive Board Member
Cluster for Individualized Immune Intervention (Ci3) e.V., Mainz, Germany (non-listed company)	Second Chairman
Vienna Medical University	Member of the Scientific Advisory Board

Prof. Christoph Huber, M.D., Dr. h. c., is a co-founder of BioNTech and has served as a member of our Supervisory Board since 2008. He has more than 50 years of professional experience in hematology, oncology and translational immunology. He was the founder and president of the leading European research network Association for Cancer Immunotherapy (“CIMT”), where he serves as an executive board member. Christoph Huber served as Chairman of the Department of Hematology and Oncology at the Johannes Gutenberg University Mainz from 1990 to 2009. He was a co-founder of Ganymed Pharmaceuticals AG, now a subsidiary of Astellas Pharma Inc. and of the non-profit translational oncology research institute TRON gGmbH. In addition, he is Second Chairman of the cutting-edge technology Cluster for Individualized Immune Intervention (Ci3) e.V. Christoph Huber earned his M.D. at the University of Innsbruck, Austria, and was a research fellow at the Wallenberg Laboratories in Uppsala, Sweden, and the Fred Hutchinson Cancer Research Center in Seattle, U.S.